EUVIMEDEUVIMED entdecken
Crossref

A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia

Anshul Vagrecha iD, Vincent Tao, Rosemarie Corless, Cassandra Colon, Arlene Redner, Mark Atlas

Expert Review of Clinical Pharmacology · 2023

DOI: 10.1080/17512433.2023.2223970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Clinical Pharmacology, 2023. Verfasst von Anshul Vagrecha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Hematology/Oncology and Cellular Therapy, Cohen Children's Medical Center, New Hyde Park, NY, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug Hypersensitivity, Erwinia, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pegylated form of E. coli derived asparaginase (PEG) is a crucial component of pediatric ALL therapy. Patients who develop a hypersensitivity (HSR) reaction with PEG receive an alternative form - Erwinia asparaginase (EA). However, an international shortage in 2017 had made it challenging to treat these patients. We have developed a comprehensive strategy to address this need. PATIENTS AND METHODS: This is a single center, retrospective analysis. All patients receiving PEG were premedicated to reduce infusion reactions. Patients who developed HSR underwent PEG desensitization. Patients were compared to historic controls. RESULTS: Fifty-six patients were treated within the study period. There was no difference in the frequency of reactions before and after the adoption of universal premedication (p = 0.78). Eight patients (14.2%) developed either ≥ Grade 2 HSR or silent inactivation and 5 patients (62.5%) successfully underwent desensitization. The remaining three patients received EA asparaginase. This intervention led to a decrease in PEG substitution, with 3 patients (5.3%) requiring EA compared to 8 patients (15.09%) in the pre-intervention period. (p = 0.11) PEG desensitization was more cost effective than EA administration. CONCLUSION: PEG desensitization is a safe, cost effective, and practical alternative in children with ALL and a Grade 2 or higher HSR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaDrug HypersensitivityErwiniaAntineoplastic AgentsChildHumansAsparaginaseEscherichia coliRetrospective StudiesPolyethylene Glycols

Stichwörter der Autor:innen

DesensitizationErwiniaPEG asparaginaseasparaginasepremedicationshortage

Substanzen

AsparaginasePolyethylene GlycolsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Hematology/Oncology and Cellular Therapy, Cohen Children's Medical Center, New Hyde Park, NY, USA.
  • Department of Pediatrics, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.

ORCID-Profile: Anshul Vagrecha

Zitieren

APA

Vagrecha, A., Tao, V., Corless, R., Colon, C., Redner, A., & Atlas, M. (2023). A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2023.2223970

Vancouver

Vagrecha A, Tao V, Corless R, Colon C, Redner A, Atlas M. A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia. Expert Review of Clinical Pharmacology. 2023. doi:10.1080/17512433.2023.2223970

BibTeX
@article{Vagrecha2023,
  author = {Vagrecha, Anshul and Tao, Vincent and Corless, Rosemarie and Colon, Cassandra and Redner, Arlene and Atlas, Mark},
  title = {A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2023},
  doi = {10.1080/17512433.2023.2223970}
}
Kostenlos starten →